Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-875 in diabetic patients
NCT01585792Phase 3Completed
- Sponsor
- Takeda
- Start
- May 2012
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fasiglifam in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Takeda. Primary endpoint: Blood glucose at 4 weeks. Started May 2012; status: completed.
02
Drugs
fasiglifam
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01585792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01585792.